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Background: China has a high burden of drug-resistant tuberculosis (TB) and diabetes mellitus (DM).
Objective: The objectives of this study were to determine the following in patients with culture-confirmed TB:
1) demographic characteristics and disease patterns in relation to the presence or absence of type 2 diabetes
and 2) presence or absence of drug resistance to isoniazid (INH), rifampicin (RMP) or both in relation to
duration of diabetes and control of diabetes.
Design: This is a cross-sectional and retrospective study involving record reviews.
Results: There were 621 patients with culture-positive TB, of whom 187 (30%) had previously known or new
type 2 diabetes. In those with diabetes, there was a significantly higher proportion of males, persons aged
]35 years and patients registered with new TB (pB0.05). Prevalence of multidrug-resistant TB (MDR-TB)
was 6.2% in new patients (N422) and 62.3% in previously treated patients (N199), with no significant
differences between those with and without diabetes. In patients with diabetes, there was no association of
drug resistance with diabetes duration or disease control [assessed by fasting blood glucose (FBG) at 1 week].
Conclusion: A high proportion of patients with TB in a tertiary health facility, Beijing, China, had diabetes,
but there was no association between type 2 diabetes and drug-resistant TB. Further prospective studies are
needed to confirm these findings.
Keywords: diabetes mellitus; diabetes duration; diabetes control; tuberculosis; multidrug-resistant tuberculosis; China
Responsible Editor: Nawi Ng, Umea˚ University, Sweden.
*Correspondence to: Fengling Mi, Department of Research, Beijing Tuberculosis and Thoracic Tumor
Research Institute, Beijing Chest Hospital, Capital Medical University, No 97, Machang, Tongzhou District,
Beijing, P.C:101149, China, Email: MFL667@163.com
Received: 26 February 2014; Revised: 22 April 2014; Accepted: 26 April 2014; Published: 19 May 2014
D
rug-resistant tuberculosis (TB), especially multi-
drug-resistant TB [MDR-TB, defined as resis-
tance to at least isoniazid (INH) and rifampicin
(RMP)], is a major threat to the control of TB worldwide
(1). China is one of the high TB and MDR-TB burden
countries in the world, with the second largest absolute
number of MDR-TB patients (2). Although China has
achieved the 2005 global TB target (70% case detec-
tion and 85% treatment success), the problem of drug-
resistant TB is a serious obstacle to achieving the
Millennium Development Goal (MDG) of halving TB
prevalence and deaths by 2015 (3, 4).
As a consequence of population growth, ageing, chang-
ing lifestyles and urbanisation, China is also witnessing
#These authors share the primary authorship.
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an escalating epidemic of diabetes mellitus (DM) (5, 6).
Available data from a recent study in a nationally rep-
resentative sample of the population show the age-
standardised prevalence of DM and prediabetes to be
9.7 and 15.5%, respectively, which extrapolates to 92
million adults with DM and 148 million with prediabetes
in the country (7).
DM is a well-known risk factor for TB. It increases the
risk of developing active TB by a factor of 23 compared
with the normal population (8). There are also reports of
DM patients with TB being more likely to develop drug-
resistant TB (911), although the numbers of patients
reported in these studies are small, and there are few data
on whether the duration of DM and control of disease
have any association with the presence of drug resistance.
The double burden of disease is a serious and growing
challenge for Chinese health systems, and DM poses a
threat for TB control in China. However, there is little
information about whether DM, duration of disease and
control of DM have any association with drug-resistant
TB. The objectives of this study, therefore, were to
describe in patients aged 15 years and above with TB
registered in Beijing Tuberculosis and Thoracic Tumor
Research Institute: 1) demographic characteristics and
patterns of TB in relation to the presence or absence of
type 2 DM, and 2) the presence or absence of drug
resistance to INH, RMP or both in relation to duration
of DM and quality of DM control.
Methods
Study design
This was a cross-sectional and retrospective study invol-
ving a record review of TB patients registered and treated
in Beijing Tuberculosis and Thoracic Tumor Research
Institute, China.
Setting  general and study site
General
China is a country of 1.3 billion people, with approxi-
mately 90 million people living with DM and each year
about 1 million estimated new cases of TB and 100,000
new incident cases of MDR-TB (2).
Study site
The study site was Beijing Tuberculosis and Thoracic
Tumor Research Institute. Beijing is the capital city of
China, which lies in the north-east of China, with a popu-
lation of 19.6 million. Beijing Tuberculosis and Thoracic
Tumor Research Institute houses 25 clinical and technical
departments and 8 scientific research departments, and
there is an integrated system for diagnosis, treatment and
basic scientific research on TB and thoracic tumour. The
institute had previously coordinated and implemented
the National Survey of drug-resistant TB in the country
(12), and had participated in a study of bidirectional
screening of DM and TB in China (13, 14). There are 955
staff members, a total of 533 inpatient beds of which 210
are available for TB patients. There are about 800 TB
patients admitted for inpatient care each year, and of
these, 450 have culture-confirmed pulmonary disease.
Patients have to pay for diagnosis and treatment in the
hospital.
Diagnosis of TB. The diagnosis of TB is made in line
with China’s TB Control Programme Guidelines (4).
Bacteriological tests for the diagnosis of TB include
smear, culture and drug susceptibility testing (DST). Each
inpatient is investigated by sputum smear and culture at
the time of hospitalisation, and if the culture is positive
for Mycobacterium tuberculosis, then DST is performed.
Smears are stained with 0.1% auramine-O and read with
LED microscopy (4), and a diagnosis of smear-positive
pulmonary TB is normally made within 3 days. For
mycobacterial culture, sputa are digested with 4% sodium
hydroxide (NaOH) for 15 min and then inoculated
to acid-buffer Lowenstein-Jensen (LJ) media (4). Drug
resistance testing is done using the proportion method
(LJ media) (15), with concentrations of INH and RMP
being 0.2 and 40 mg/ml, respectively. The result of an
external quality assessment (EQA) of DST by the TB
National Reference Laboratory in 2012 showed that the
accordance rates for both INH and RMP were above
90%. Once patients are diagnosed with TB, they are
categorised as either new or retreatment cases according
to the patient’s treatment history.
Diagnosis for DM. The diagnosis of type 2 DM follows
national guidelines which stipulates that a fasting blood
glucose (FBG) test is carried out using venous plasma
and a biochemical analyzer with a cut-off threshold
in line with that recommended by the World Health
Organization (WHO) (16). The diagnosis is based on the
following: (1) determining whether patients are already
known to have type 2 DM, (2) in those with no known
history of DM, measuring an FBG (14), and (3) in those
with previously known type 2 DM, measuring an FBG
and asking the patient the duration of type 2 DM. As
part of routine assessments, every inpatient is asked to
undergo FBG. For a diagnosis of type 2 DM to be made,
a patient has to have two FBG measurements ]7.0
mmol/L (126 mg/dL) at different time intervals. The dia-
gnosis of type 2 DM in newly identified patients usually
takes 1 week. Newly diagnosed type 2 DM patients are
defined as having a duration of disease less than or equal
to 1 month while previously known type 2 DM patients
are defined as having a duration of disease from the time
that type 2 DM was first diagnosed providing that this
was longer than 1 month.
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Patients
All inpatients aged 15 years or older and registered with
mycobacterial culture-confirmed TB in Beijing Tubercu-
losis and Thoracic Tumor Research Institute between
1 January 2011 and 30 June 2012 (18 months) were
included in the study.
Data sources, data variables and data collection
Data were obtained from the medical records, the drug-
resistant TB register and the electronic system of medical
records in Beijing Tuberculosis and Thoracic Tumor
Research Institute. Data variables included: 1) TB status:
registration number of the medical record; date of
registration; age; sex; ethnic nationality group (the Han
ethnic group and others); occupation (manual worker,
office worker, farmer, unemployed worker and others);
residence (a Beijing resident and others); category of TB
(new or previously treated); history of TB treatment with
one of four drugs (INH; RMP; ethambutol, EMB; and
pyrazinamide, PZA); 2) drug-resistant status of TB: no
resistance; resistance to INH; resistance to RMP; MDR-
TB; 3) DM status at the time of TB registration: dia-
gnosis of type 2 DM (Yespreviously known or new
diagnosis; Nonone of these) for those with type 2 DM,
the measurement of FBG in the first week of treatment
and the duration of disease from when it was first
diagnosed. Data were collected into a paper proforma
and an EXCEL electronic tool by six staff members (four
resident physicians, two researchers) of Beijing Tuberculosis
and Thoracic Tumor Research Institute.
Analysis and statistics
Descriptive analysis was performed. Comparisons were
made for patterns of TB in patients with and without type
2 DM. Comparisons were made between drug-sensitive
and drug-resistant TB in relation to quality of DM
control as determined by FBG and duration of DM. DM
control was arbitrarily defined as: DM good control,
FBGB7.0 mmol/L; DM poor control, FBG 710 mmol/
L; DM bad control, FBG 10 mmol/L. Statistical com-
parisons between categorical variables were made using
the chi-square test for univariate analysis followed by
multivariate regression. In logistic regression models, all
variables that were significant in the univariate analysis
were adjusted for using odds ratios (OR) and 95%
confidence intervals (95% CI). Levels of significance
were set at 5%.
Results
Demographic characteristics, patterns of disease
and drug resistance profiles of TB patients with and
without type 2 DM
There were 621 patients with culture-positive TB. With
the exception of one patient with no information about
DM, there were 187 (30%) patients with type 2 DM.
Demographic characteristics, patterns of disease and
drug resistance profiles of TB patients with and without
type 2 DM are shown in Table 1. On univariate analysis,
males, persons aged 35 years and above, manual workers
and Beijing residents with TB had a higher prevalence of
DM compared with their reference population. Similarly,
there was a higher proportion of patients with new TB
compared with previously treated TB in those with DM.
The results of multivariate analysis are also shown in
Table 1, with males, persons aged 35 years and above,
Beijing residents and new patients having a significantly
higher prevalence of type 2 DM. Prevalence of single
drug resistance to INH or RMP and MDR-TB was 10.0
and 6.2%, respectively, in new patients (N422) and 12.0
and 62.3%, respectively, in previously treated patients
(N199), with no significant differences between those
with and without type 2 DM.
Type 2 DM patients with drug-resistant disease in
relation to duration and control of DM
Amongst TB patients with type 2 DM, there were 23
patients (12.3%) who were resistant to INH or RMP and
31 patients (16.6%, 31/187) who had MDR-TB. In those
with type 2 DM, there was no statistical association
between duration of disease and patterns of pan-sensitive,
drug-resistant or MDR-TB, when comparing patients
with duration of disease for less than 1 month to those
with a longer duration (Table 2). Likewise, control of DM
as judged by FBG measurements done in the first week of
treatment was not statistically different in patients with
pan-sensitive, drug-resistant or MDR-TB, when compar-
ing patients with good DM control to those with poor or
bad DM control (Table 2).
Discussion
This is one of the first studies in Beijing, China, to assess
the relationship between type 2 DM and drug-sensitive/
drug-resistant TB in patients with culture-confirmed M.
tuberculosis. TB patients with type 2 DM were more likely
to be male, older than 35 years of age, a manual worker, a
Beijing resident and to have new TB compared with those
who did not have DM. Otherwise, we found no sig-
nificant association between type 2 DM and the patterns
of drug-sensitive/drug-resistant TB, and in those with
type 2 DM no association between drug-sensitive/drug-
resistant TB and duration of DM or quality of DM
control.
The strengths of this study were the large number of
TB patients who were consecutively registered and
enrolled to treatment in a high-level hospital in China.
All patients were investigated in the same manner with
smears, cultures of M. tuberculosis and DST carried out
in a quality-assured laboratory using methods that were
in line with WHO guidelines. Tests for FBG were carried
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out in all patients in line with the routine practice in the
hospital. The data were collected through the electronic
system and checked with the information recorded in
paper-based registers, so we believe that the information
is credible. The conduct of this observational study and
the study report also followed STROBE guidelines (17).
Limitations related to the operational nature and
cross-sectional design of the study. All patients were
hospitalised, as it would have been difficult to get all tests
done and recorded on outpatients, but this introduces
an element of bias into the study population as more
patients would have been sick compared with TB patients
in general and they also had to pay for diagnosis and
treatment. Thus, our patients may not have been repre-
sentative of the general population as poor patients
would not have been included. A further limitation was
that DM control was based on measurements of FBG,
whereas measurements of glycated haemoglobin (HbA1C)
would have been better and would have provided a more
reliable assessment of DM control. However, HbA1C is
expensive, and although some patients did have this test
performed in the hospital setting, the majority did not.
Finally, the cross-sectional design of our study limits the
conclusions that can be drawn about associations be-
tween DM and drug-resistant TB. In contrast with the
findings from our study, there was a previous study from
China reporting that the frequency of MDR-TB among
DM patients with TB was higher than that among TB
Table 1. Characteristics of TB patients with and without type 2 DM, Beijing, China
Characteristics
Total number,
N621
TB with DM number
(%), N187
Univariate OR
(95% CI)
Adjusted OR
(95% CI)
Demographic characteristics
Sex
Female 171 28 (16.4) Reference
Male 450 159 (35.3) 2.8 (1.84.4) 2.1 (1.33.4)
Age
1534 155 11 (7.1) Reference
3554 196 82 (41.8) 9.4 (4.818.5) 7.7 (3.815.5)
]55 270 94 (34.8) 7.0 (3.613.6) 5.0 (2.510.0)
Ethnic group
Han ethnic group 591 180 (30.5) Reference
Others 30 7 (23.3) 0.7 (0.31.6)
Occupation
Office worker 86 22 (25.6) Reference
Manual worker 90 40 (44.4) 2.3 (1.24.4) 0.6 (0.31.2)
Farmer 110 30 (27.3) 1.1 (0.62.1) 0.5 (0.31.0)
Unemployed worker 139 39 (28.1) 1.1 (0.62.1) 0.7 (0.41.3)
Others 193 56 (29.0) 1.2 (0.72.1) 0.6 (0.41.1)
Resident
Beijing resident 335 131 (39.1) Reference
Others 286 56 (19.6) 0.4 (0.30.6) 0.6 (0.40.9)
Category of TB
New 422 144 (34.1) Reference
Previously treated 199 43 (21.6) 0.5 (0.40.8) 0.6 (0.40.9)
Drug resistance
Patients with new cases of tuberculosis
Susceptibility to isoniazid/rifampicin 354 118 (33.3) Reference
Isoniazid resistance 37 14 (37.8) 1.2 (0.62.5)
Rifampicin resistance 5 2 (40.0) 1.3 (0.28.1)
Multidrug resistant 26 10 (38.5) 1.3 (0.62.8)
Patients with previously treated tuberculosis
Susceptibility to isoniazid/rifampicin 51 15 (29.4) Reference
Isoniazid resistance 13 5 (38.5) 1.5 (0.45.3)
Rifampicin resistance 11 2 (18.2) 0.5 (0.12.8)
Multidrug resistant 124 21 (16.9) 0.5 (0.21.1)
TB: Tuberculosis; DM: diabetes mellitus; CI: confidence intervals.
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patients without DM (17.7 versus 8.4%, pB0.01) (10).
Several other studies have also shown this association
(11, 18), with one of these studies even suggesting that
patients with DM may be eight times more likely to have
infection with MDR-TB (18). In Eastern Taiwan, there
was a recent paper reporting an association between DM
and INH resistance in new and previously treated TB
patients, but no association was found between DM and
MDR-TB (19). Reasons for the association of DM and
drug resistance are speculative and may be because DM
patients do not achieve or maintain adequate blood levels
of RMP as a result of drugdrug interactions between
anti-TB drugs and oral hypoglycaemic drugs, bacterial
genetics, strain mutations and immune impairment as a
result of DM (11, 20, 21). It might also be expected that
with delayed sputum culture conversion and increased
rates of treatment failure (22, 23), which have been docu-
mented in cohorts of TB patients with DM, that DM
patients with recurrent or previously treated TB might be
at a higher risk of drug resistance and MDR-TB.
A systematic review of four studies, however, found no
association between DM-TB and drug-resistant TB in
patients with recurrent disease (22). In countries such as
India, Japan and USA, there have also been no studies
documenting a positive association between recurrent
drug-resistant TB and MDR-TB when DM patients are
compared with non-DM patients (11, 19, 2426). Indeed,
there have been reports of a lower prevalence of drug
resistance in TB patients with DM (27).
It is possible that these different and contrasting
findings in generally well-conducted studies are because
other important determinants of TB treatment outcomes
 that include death, failure and recurrent disease  and
their linkage to the possibility of drug resistance have
not been factored in when comparing DM with no DM.
For example, there is an established association between
cigarette smoking and TB treatment outcomes including
an increased risk of death (28) and an increased risk of
relapse after successful completion of treatment (29). A
recent study from Korea showed that DM and smoking
independently increased the risk of death in TB patients,
with the combined impact of both determinants yielding
a hazard ratio for death of almost six (30).
While this current study suggests that there is no
increased risk of drug-resistant TB in patients with type 2
DM, it would be unwise to be complacent on this issue.
There is a sizeable and growing burden of drug-resistant
TB in China, and this has implications for the manage-
ment of DM patients. Good infection control measures
must be adopted and practiced in DM clinics to prevent
any nosocomial spread of TB, and DM patients who
are responding poorly to anti-TB treatment should be
considered and investigated for drug-resistant disease.
Further prospective research using a cohort design with
adequate follow-up is needed, which includes all known
determinants for drug-resistant TB in DM patients so
that a better understanding is reached about the interac-
tions between the two diseases.
Table 2. Patients with and without drug-resistant TB in relation to duration and control of diabetes, Beijing, China
Single-drug resistant TBa Multidrug-resistant TBb
DM patients
Number of
patients
Pan-sensitive TB
number (%)
Number
(%)
Versus pan-sensitive TB
Odds ratio (95% CI)
Number
(%)
Versus pan-sensitive TB
Odds ratio (95% CI)
DM duration
DM duration
51 month
44 34 (77.2) 5 (11.4) Reference 5 (11.4) Reference
DM duration
1 month and
B5 years
57 36 (63.1) 9 (15.8) 1.7 (0.55.6) 12 (21.1) 2.3 (0.77.1)
DM duration
]5 years
86 63 (73.2) 9 (10.5) 1.0 (0.33.1) 14 (16.3) 1.5 (0.54.6)
DM quality control
DM good controlc 49 33 (67.3) 7 (14.3) Reference 9 (18.4) Reference
DM poor controld 70 48 (68.6) 11 (15.7) 1.1 (0.43.1) 11 (15.7) 0.8 (0.32.3)
DM bad controle 68 52 (76.5) 5 (7.3) 0.5 (0.11.6) 11 (16.2) 0.8 (0.32.1)
DM: diabetes mellitus; TB: tuberculosis.
aSingle-drug-resistant TB resistant to either isoniazid or rifampicin.
bMultidrug-resistant TB resistant to at least isoniazid and rifampicin.
cDM good control: Fasting blood glucose 57.0 mmol/L in first week of treatment.
dDM poor control: Fasting blood glucose 7.110.0 mmol/L in first week of treatment.
eDM bad control: Fasting blood glucose 10.0 mmol/L in first week of treatment.
Diabetes and drug resistance in China
Citation: Glob Health Action 2014, 7: 24022 - http://dx.doi.org/10.3402/gha.v7.24022 5
(page number not for citation purpose)
Conclusion
In Beijing, China, hospitalised TB patients with DM were
more likely to be male, older, a Beijing resident, of worker
occupation and to have new TB compared with TB
patients who did not have type 2 DM. We found no
association between type 2 DM and drug-sensitive/drug-
resistant TB, and in those with type 2 DM there was no
association between drug-resistant status and duration of
DM or control of DM, the latter determined by FBG in
the first week of anti-TB treatment. Further prospective
research is needed on the association between DM and
drug-resistant TB, and this research will need to factor in
other determinants of drug resistance in order to better
understand the interactions between the two diseases.
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